Skip to main content
TipRanks
Go Ultimate75% OFF

Kohjin Bio Co.,Ltd. (177A) AI Stock Analysis

0 Followers
JP:177A

Kohjin Bio Co.,Ltd.

(TSE/TYO:177A)

Select Model
Rating:48Neutral
Price Target:JPY 533.00â–²(3.29% Upside)
Action:reiterated
Date:11/19/26

Kohjin Bio's overall score reflects a highly challenging setup. While its robust balance sheet and low debt levels provide a strong structural foundation, significant concerns stem from negative free cash flow, severe margin compression, and a deeply bearish technical downtrend. The negative P/E ratio further detracts from its near-term investment appeal.

Positive Factors
Improving Balance SheetFalling leverage and a significantly larger equity base indicate improved financial resilience. This gives Kohjin Bio more capacity to absorb operating volatility, maintain investment, and fund strategic priorities without relying as heavily on additional borrowing.
Negative Factors
Revenue ContractionA return to declining revenue signals weaker business momentum and reduces the scale available to support fixed costs, research, and commercial investment. Unless growth recovers, the contraction can make profitability more vulnerable and limit the company’s ability to compound earnings.

Kohjin Bio Co.,Ltd. (177A) vs. iShares MSCI Japan ETF (EWJ)

-80%-60%-40%-20%0%20%40%JP:177A-66.28%EWJ+11.03%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 2.58B
Dividend Yield
1.94%
Average Volume (3M)
3,728
Price to Earnings (P/E)
-87.4
Beta (1Y)
0.38
Revenue Growth
-15.78%
EPS Growth
-104.11%
Country
Japan
Employees
176
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Kohjin Bio Co.,Ltd. Business Overview & Revenue Model

Company Description

Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materi...

How the Company Makes Money

null

Kohjin Bio Co.,Ltd. Financial Statement Overview

Summary

Kohjin Bio exhibits a mixed financial profile. A pristine balance sheet with low leverage provides a strong structural foundation, but this is significantly offset by weakening operational metrics, declining revenue, margin compression, and deeply negative free cash flow.

Income Statement

42Neutral

Balance Sheet

85Very Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2026Mar 2025Mar 2023Mar 2022
Income Statement
Total Revenue5.20B5.21B4.94B4.77B4.74B3.95B
Gross Profit2.32B2.37B1.86B1.88B2.45B2.04B
EBITDA1.30B1.41B766.46M958.10M1.44B1.14B
Net Income718.77M794.76M251.02M384.00M829.79M587.67M
Balance Sheet
Total Assets8.84B9.12B8.90B6.64B6.20B5.60B
Cash, Cash Equivalents and Short-Term Investments2.59B3.15B2.49B1.73B1.46B1.73B
Total Debt1.95B2.39B2.19B2.47B2.10B2.23B
Total Liabilities3.03B3.34B2.96B3.30B3.18B3.38B
Stockholders Equity5.81B5.78B5.95B3.34B3.02B2.22B
Cash Flow
Free Cash Flow028.05M-280.78M260.88M-99.57M559.44M
Operating Cash Flow0915.55M698.51M823.68M461.15M762.98M
Investing Cash Flow0-1.09B-867.67M-577.35M-575.46M82.78M
Financing Cash Flow01.38B-320.76M-1.35M-172.21M-360.17M

Kohjin Bio Co.,Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price516.00

Price Trends

50DMA774.54Negative
100DMA826.46Negative
200DMA1024.34Negative

Market Momentum

MACD-60.00Positive
RSI11.63Positive
STOCH3.42Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:177A, the sentiment is Negative. The current price of 516.00 is below the 20-day moving average (MA) of 698.95, below the 50-day MA of 774.54, and below the 200-day MA of 1024.34, indicating a bearish trend. The MACD of -60.00 indicates Positive momentum. The RSI at 11.63 is Positive, neither overbought nor oversold. The STOCH value of 3.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:177A.

Kohjin Bio Co.,Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:177A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:177AJP:177A48NeutralJPY 2.64B-87.37―1.94%-15.78%-104.11%
JP:4978JP:497845NeutralJPY 11.75B-24.37――-8.23%-48.10%
JP:7774JP:777442NeutralJPY 26.03B-70.96――17.05%10.47%
JP:4599JP:459939UnderperformJPY 7.77B-4.21―――4.85%
JP:7776JP:777637UnderperformJPY 6.07B-4.74――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:177AJP:4599JP:4978JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:177A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:177AKohjin Bio Co.,Ltd.516.00-1025.99-66.54%
JP:4599StemRIM Inc.124.00-155.00-55.56%
JP:4978ReproCELL Inc.110.00-45.00-29.03%
JP:7774Japan Tissue Engineering Co., Ltd.641.00155.0031.89%
JP:7776CellSeed Inc.153.00-141.00-47.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026